Cobalt metabolism and toxicology-A brief update

Science of the Total Environment

Volumn 432, Issue , 2012, Pages 210-215

  Simonsen, Lars Ole ^a   Harbak, Henrik ^a   Bennekou, Poul ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomonitoring; Cobalt; Erythrocytes; Erythropoietin; Humans; Hypoxia; Metabolism; Toxicology

Indexed keywords

BIOMONITORING; ERYTHROCYTES; ERYTHROPOIETIN (EPO); HUMANS; HYPOXIA; TOXICOLOGY;

BODY FLUIDS; CALCIUM; CARDIOVASCULAR SYSTEM; CELL DEATH; CHROMIUM; DEBRIS; HISTOLOGY; IONIZATION; JOINT PROSTHESES; MAMMALS; METABOLISM; METAL IONS; METALS; SALTS; TISSUE; TOXICITY;

COBALT;

ALBUMIN; COBALT; REACTIVE OXYGEN METABOLITE;

BIOLOGICAL UPTAKE; BIOMONITORING; CARCINOGEN; COBALT; CORROSION; DNA; GENOTOXICITY; HYPOXIA; MEMBRANE; METABOLISM; SERUM; TOXICOLOGY;

APOPTOSIS; BIOACCUMULATION; BIOLOGICAL MONITORING; BLOOD ANALYSIS; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARCINOGENICITY; CELLULAR DISTRIBUTION; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DNA DAMAGE; DOPING; GENOTOXICITY; HUMAN; METABOLISM; METAL INDUSTRY; NANOTOXICOLOGY; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; TISSUE DISTRIBUTION; TOXICOLOGY;

ANIMALS; COBALT; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; ERYTHROCYTES; HUMANS;

ANIMALIA; MAMMALIA;

EID: 84862591820     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2012.06.009     Document Type: Review

References (84)

1. Akbar M., Brewer J.M., Grant M.H. Effect of chromium and cobalt ions on primary human lymphocytes in vitro. J Immunotoxicol 2011, 8:140-149.
2. Alexandersson R. Blood and urinary concentrations as estimators of cobalt exposure. Arch Environ Health 1988, 43:299-303.
3. ATSDR, Agency for Toxic Substances and Disease Registry Toxicological profile for cobalt 2004, 1-417. U.S. Department of Health and Human Services, Public Health Service, http://www.atsdr.cdc.gov/toxprofiles/tp33.pdf.
4. Ayala-Fierro F., Firriolo J.M., Carter D.E. Disposition, toxicity, and intestinal absorption of cobaltous chloride in male Fisher 344 rats. J Toxicol Environ Health A 1999, 56:571-591.
5. Barceloux D.G. Cobalt. Clin Toxicol 1999, 37:201-216.
6. Berk L., Burchenal J.H., Castle W.B. Erythropoietic effect of cobalt in patients with or without anemia. N Engl J Med 1949, 240:754-761.
7. Billi F., Campbell P. Nanotoxicology of metal wear particles in total joint arthroplasty: a review of current concepts. J Appl Biomater Biomech 2010, 8:1-6.
8. Bryan S.E., Good M.L., Morgan K.S., Morton F. Cobalt deposition in rat erythrocytes and cardiac tissue as evidence for the biosynthesis of cobalt porphyrins. FEBS Lett 1970, 6:270-272.
9. Caicedo M.S., Pennekamp P.H., McAllister K., Jacobs J.J., Hallab N.J. Soluble ions more than particulate cobalt-alloy implant debris induce monocyte costimulatory molecule expression and release of proinflammatory cytokines critical to metal-induced lymphocyte reactivity. J Biomed Mater Res 2010, 93A:1312-1321.
10. Catelas I., Petit A., Vali H., Fragiskatos C., Meilleur R., Zukor D.J., et al. Quantitative analysis of macrophage apoptosis vs. necrosis induced by cobalt and chromium ions in vitro. Biomaterials 2005, 26:2441-2453.
11. Christensen J.M. Human exposure to toxic metals: factors influencing interpretation of biomonitoring results. Sci Total Environ 1995, 166:89-135.
12. Cobb A.G., Schmalzreid T.P. The clinical significance of metal ion release from cobalt-chromium metal-on-metal hip joint arthroplasty. J Eng Med 2006, 220-H:385-398.
13. Colognato R., Bonelli A., Ponti J., Farina M., Bergamaschi E., Sabbioni E., et al. Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leucocytes in vitro. Mutagenesis 2008, 23:377-382.
14. Daniel J., Ziaee H., Pynsent P.B., McMinn D.J.W. The validity of serum levels as a surrogate measure of systemic exposure to metal ions in hip replacement. J Bone Joint Surg Br 2007, 89-B:736-741.
15. Davis J.E., Fields J.P. Experimental production of polycythemia in humans by administration of cobalt chloride. Proc Soc Exp Biol Med 1958, 99:493-495.
16. Duckham J.M., Lee H.A. The treatment of refractory anaemia of chronic renal failure with cobalt chloride. Q J Med 1976, 45:277-294.
17. Edel J., Pozzi G., Sabbioni E., Pietra R., Devos S. Metabolic and toxicological studies on cobalt. Sci Total Environ 1994, 150:233-244.
18. 2+. Am J Physiol Heart Circ Physiol 2000, 279:H2713-H2719.
19. Epstein A.C.R., Gleadle J.M., McNeill L.U., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-54.
20. Fisher J.W., Langston J.W. Effects of testosterone, cobalt and hypoxia on erythropoietin production in the isolated perfused dog kidney. Ann N Y Acad Sci 1968, 149:75-87.
21. Gill H.S., Grammatopoulos G., Adshead S., Tsialogiannis E., Tsiridis E. Molecular and immune toxicity of CoCr nanoparticles in MoM hip arthroplasty. Trends Mol Med 2012, 18:145-155.
22. Haddad F.S., Thakrar R.R., Hart A.J., Skinner J.A., Nargol A.V.F., Nolan J.F., et al. Metal-on-metal bearings: the evidence so far. J Bone Joint Surg Br 2011, 93-B:572-579.
23. Hille B. Ionic channels of excitable membranes 1992, Sinauer, Sunderland, Mass. 2nd ed.
24. Hojman P., Brolin C., Gissel H., Brandt C., Zerahn B., Pedersen B.K. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009, 4(6):e5894.
25. Hollins J.G., McCullough R.S. Radiation dosimetry of internal contamination by inorganic compounds of cobalt: an analysis of cobalt metabolism in rats. Health Phys 1971, 21:233-246.
26. Hu X.V., Chen X., Han K.C., Mildvan A.S., Liu J.O. Kinetic and mutational studies of the number of interacting divalent cations required by bacterial and human methionine aminopeptidases. Biochemistry 2007, 46:12833-12843.
27. Huk O.L., Catelas I., Mwale F., Antoniou J., Zukor D.J., Petit A. Induction of apoptosis and necrosis by metal ions in vitro. J Arthroplasty 2004, 19:84-87.
28. IARC, International Agency for Research on Cancer Cobalt in hard-metals and cobalt sulphate, gallium arsenide, indium phosphide and vanadium pentoxide. Monogr Eval Carcinog Risk Chem Hum 2006, 86:1-300.
29. Ichikawa Y., Kusaka Y., Goto S. Biological monitoring of cobalt exposure, based on cobalt concentrations in blood and urine. Int Arch Occup Environ Health 1985, 55:269-276.
30. Ivanov I.T. Allometric dependence of the life span of mammalian erythrocytes on thermal stability and sphingomyelin content of plasma membranes. Comp Biochem Physiol A Comp Physiol 2007, 147:876-884.
31. Jansen H.M.L., Knollema S., van der Duin L.V., Willemsen A.T.M., Wiersma A., Franssen E.J.F., et al. Pharmacokinetics and dosimetry of cobalt-55 and cobalt-57. J Nucl Med 1996, 37:2082-2086.
32. Jarvis J.Q., Hammond E., Meier R., Robinson C. Cobalt cardiomyopathy. A report of two cases from mineral assay laboratories and a review of the literature. J Occup Med 1992, 34:620-626.
33. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007, 78:183-205.
34. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402.
35. Kaplan S.M., Piliero S.J., Gordon A.S., Meagher R. Mechanisms underlying suppression of erythropoiesis by hyperoxia. Am J Med Sci 1977, 273:71-77.
36. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006, 70:1469-1480.
37. Keegan G.M., Learmonth I.D., Case C.P. Orthopaedic metals and their potential toxicity in the arthroplasty patient: a review of current knowledge and future strategies. J Bone Joint Surg Br 2007, 89-B:567-573.
38. Keegan G.M., Learmonth I.D., Case C.P. A systematic comparison of the actual, potential, and theoretical health effects of cobalt and chromium exposures from industry and surgical implants. Crit Rev Toxicol 2008, 38:645-674.
39. Kobayashi M., Shimizu S. Cobalt proteins. Eur J Biochem 1999, 261:1-9.
40. Kwon Y.-M., Xia Z., Glyn-Jones S., Beard D., Gill H.S., Murray D.W. Dose-dependent cytotoxicity of clinically relevant cobalt nanoparticles and ions on macrophages in vitro. Biomed Mater 2009, 4(1-8):025018.
41. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 2002, 295:858-861.
42. Langton D.J., Joyce T.J., Jameson S.S., Lord J., Van Orsouw M., Holland J.P. Adverse reaction to metal debris following hip resurfacing: the influence of component type, orientation and volumetric wear. J Bone Joint Surg Br 2011, 93-B:164-171.
43. Lauwerys R., Lison D. Health risks associated with cobalt exposure-an overview. Sci Total Environ 1994, 150:1-6.
44. Lee C.-C., Wolterink L.F. Blood and tissue partition of cobalt 60 in dogs. Am J Physiol 1955, 183:173-177.
45. Leggett R.W. The biokinetics of inorganic cobalt in the human body. Sci Total Environ 2008, 389:259-269.
46. Letourneau E.G., Jack G.C., McCullough R.S., Hollins J.G. The metabolism of cobalt by the normal human male: whole body retention and radiation dosimetry. Health Phys 1972, 22:451-459.
47. Linna A., Oksa P., Groundstroem K., Halkosaari M., Palmroos P., Huikko S., et al. Exposure to cobalt in the production of cobalt and cobalt compounds and its effect on the heart. Occup Environ Med 2004, 61:877-885.
48. Lippi G., Franchini M., Guidi G.C. Cobalt chloride administration in athletes: a new perspective in blood doping?. Br J Sports Med 2005, 39:872-873.
49. Lippi G., Franchini M., Guidi G.C. Blood doping by cobalt. Should we measure cobalt in athletes?. J Occup Med Toxicol 2006, 1:18-20.
50. Lippi G., Montagnana M., Guidi G.C. Albumin cobalt binding and ischaemia modified albumin generation: an endogenous response to ischaemia?. Int J Cardiol 2006, 108:410-411.
51. Martin A., Bois F.Y., Pierre F., Wild P. Occupational exposure to cobalt: a population toxicokinetic modeling approach validated by field results challenges the biological exposure index for urinary cobalt. J Occup Environ Hyg 2010, 7:54-62.
52. Matsumoto M., Makino Y., Tanaka T., Tanaka H., Ishizaka N., Noiri E., et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 2003, 14:1825-1832.
53. Maxwell P., Salnikow K. HIF-1. An oxygen and metal responsive transcription factor. Cancer Biol Ther 2004, 3:29-35.
54. Merritt K., Brown S.A., Sharkey N.A. The binding of metal salts and corrosion products to cells and proteins in vitro. J Biomed Mater Res 1984, 18:1005-1015.
55. Miskowiak K., Inkster B., O'Sullivan U., Selvaraj S., Goodwin G.M., Harmer C.J. Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res 2008, 184:313-321.
56. Mocini D., Leone T., Tubaro M., Santini M., Penco M. Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr Med Chem 2007, 14:2278-2287.
57. Mogensen J., Miskowiak K., Sorensen T.A., Lind C.T., Olsen N.V., Springborg J.B., et al. Erythropoietin improves place learning in fimbria-fornix-transected rats and modifies the search pattern of normal rats. Pharmacol Biochem Behav 2004, 77:381-390.
58. Mohiuddin S.M., Taskar P.K., Rheault M., Roy P.-E., Chenard J., Morin Y. Experimental cobalt cardiomyopathy. Am Heart J 1970, 80:532-543.
59. Mosconi G., Bacis M., Vitali M.T., Leghissa P., Sabbioni E. Cobalt excretion in urine: results of a study on workers producing diamond grinding tools and on control group. Sci Total Environ 1994, 150:133-139.
60. Nakamura M., Yasukochi Y., Minakami S. Effect of cobalt on heme biosynthesis in rat liver and spleen. J Biochem 1975, 78:373-380.
61. ++ binding by plasma proteins. Bioinorg Chem 1972, 2:149-157.
62. Petit A., Mwale F., Tkaczyk C., Antoniou J.A., Zukor D.J., Huk O.L. Induction of protein oxidation by cobalt and chromium ions in human U937 macrophages. Biomaterials 2005, 26:4416-4422.
63. Polyzios I., Nikolopoulos D., Michos I., Patsouris E., Theocharis S. Local and systemic toxicity of nanoscale debris particles in total hip arthroplasty. J Appl Toxicol 2012, 32:255-269.
64. Sauni R., Linna A., Oksa P., Nordman H., Tuppurainen M., Uitti J. Cobalt asthma-a case series from a cobalt plant. Occup Med 2010, 60:301-306.
65. Saxena S., Shukla D., Saxena S., Khan Y.A., Sing M., Bansal A., et al. Hypoxia preconditioning by cobalt chloride enhances endurance performance and protects skeletal muscles from exercise-induced oxidative damage in rats. Acta Physiol 2010, 200:249-263.
66. Schlueter R.J., Norgello H., White W.F. Erythropoietin. I. Analysis of radioiron assay in fasted rats, using cobalt as a reference standard. Proc Soc Exp Biol Med 1960, 103:43-46.
67. Seghizzi P., D'Adda F., Borleri D., Barbic F., Mosconi G. Cobalt cardiomyopathy. A critical review of literature. Sci Total Environ 1994, 150:105-109.
68. Semenza G.L. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007, 407:cm8.
69. Shrivastava K., Shukla D., Bansal A., Sairam M., Banerjee P.K., Ilavazhagan G. Neuroprotective effect of cobalt chloride on hypobaric hypoxia-induced oxidative stress. Neurochem Int 2008, 52:368-375.
70. Siddiq A., Aminova L.R., Ratan R.R. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res 2007, 32:931-946.
71. Simonsen L.O., Brown A.M., Harbak H., Kristensen B.I., Bennekou P. Cobalt uptake and binding in human red blood cells. Blood Cells Mol Dis 2011, 46:266-276.
72. 2+ influx. Blood Cells Mol Dis 2011, 47:214-225.
73. Singh M., Shukla D., Thomas P., Saxena S., Bansal A. Hypoxic preconditioning facilitates acclimatization to hypobaric hypoxia in rat heart. J Pharm Pharmacol 2010, 62:1729-1739.
74. Smith T., Edmonds C.J., Barbaby C.F. Absorption and retention of cobalt in man by whole-body counting. Health Phys 1972, 22:359-367.
75. Söremark R., Diab M., Arvidson K. Autoradiographic study of distribution patters of metals which occur as corrosion products from dental restorations. Scand J Dent Res 1979, 87:450-458.
76. Stenberg T. The distribution in mice of radioactive cobalt administered by two different methods. Acta Odontol Scand 1983, 41:143-148.
77. Stockmann C., Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 2006, 33:968-979.
78. 2+ treatment in the rat diaphragm and hind-leg muscles. Jpn J Physiol 2002, 52:409-419.
79. 2+ treatment in rat skeletal muscles. Acta Physiol Scand 2004, 181:225-232.
80. Taylor A., Marks V. Cobalt: a review. J Human Nutr 1978, 32:165-177.
81. Thomas P., Bansal A., Singh M., Shukla D., Saxena S. Preconditioning effect of cobalt chloride supplementation on hypoxia induced oxidative stress in male albino rats. Biomed Prev Nutr 2011, 1:84-89.
82. Walter L.R., Marel E., Harbury R. Distribution of chromium and cobalt ions in various blood fractions after resurfacing hip arthroplasty. J Arthroplasty 2008, 23:814-821.
83. Weissbecker L. Die Kobalttherapie. Dtsch med Wschr 1950, 75:116-118.
84. WHO Cobalt and inorganic cobalt compounds. Concise international chemical assessment document 2006, 69:1-85. http://www.who.int/ipcs/publications/cicads69%20.pdf.